SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does.

SCHD has a 20.7% healthcare allocation, its largest sector weight, led by Merck at 4.1% and UnitedHealth at 3.9%, despite excluding dividend stalwarts Johnson & Johnson and Medtronic. Merck faces a material 2028 Keytruda patent-expiry risk, with the drug contributing $8.4 billion of its $16.6 billion in Q2 sales, while UnitedHealth continues to face Medicare Advantage cost and growth concerns. The article argues SCHD's annual index reconstitution and quality screens should allow it to replace holdings if their fundamentals deteriorate, preserving the ETF's dividend-paying capacity.

Analysis

The relevant signal is not a near-term SCHD flow event; annual, rules-based reconstitution makes any forced rotation slow and largely anticipated. The more important issue is concentration of its healthcare exposure in two names with idiosyncratic earnings-risk profiles, creating a mismatch between the ETF's defensive-dividend perception and its underlying patent, reimbursement, and medical-cost sensitivity. A negative revision cycle at MRK or UNH would pressure SCHD relative to lower-healthcare dividend ETFs even if the broad market is stable.

MRK's valuation increasingly rests on credible replacement of a concentrated oncology cash-flow stream before the exclusivity event. Pipeline execution can support the multiple over the next 12-24 months, but failure to show durable non-Keytruda growth would create a longer-duration de-rating rather than a one-quarter earnings miss. UNH has the more immediate 1-3 month risk: Medicare Advantage utilization, reimbursement-rate assumptions, and regulatory scrutiny can all force medical-loss-ratio or guidance resets, with spillover to HUM, CVS and CI.

The contrarian opportunity is in the names excluded by yield-and-growth screens rather than an outright SCHD short. JNJ's lower starting yield can be a structural screen disadvantage despite a balance-sheet and cash-flow profile that is better suited to absorbing macro or policy volatility. MDT offers a different setup: procedure-volume normalization and operating leverage matter more than reimbursement headlines, making it a cleaner defensive-healthcare substitute if managed-care risk remains elevated.

Treat the article as a positioning watch item, not an alpha catalyst. Validate current SCHD weights, index methodology changes, and relative valuations before acting; the stated company-quality claims do not independently establish an imminent rebalance or dividend-risk event.

Key Decisions for Investors

• Implement a 6-12 month defensive-healthcare pair: long JNJ / short MRK in equal beta-adjusted dollars. Thesis is cash-flow durability versus patent-cliff multiple risk; target 10-15% relative return, with stop/review if MRK demonstrates sustained material revenue contribution from new launches or JNJ faces an adverse litigation reserve revision.
• Prefer MDT over UNH for healthcare exposure over the next 3-6 months. Use a long MDT / short UNH pair only after confirming UNH's next medical-cost and Medicare Advantage guidance; target 12% relative upside, but exit on evidence that UNH's utilization trend has normalized and MDT procedure growth misses expectations.
• Do not short SCHD on this information alone. Set an alert if MRK plus UNH remain above roughly 7-8% of assets while either company cuts forward EPS guidance; that combination would raise the probability of SCHD relative underperformance versus VIG or DGRO during the subsequent rebalance window.
• For portfolios requiring dividend-ETF exposure, consider partial SCHD substitution into VIG or a direct JNJ/MDT basket for 6-18 months, pending comparison of healthcare weights, factor exposures, and tracking-error budget.